A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease

BACKGROUND: A clinical decision support tool (CDST) has been validated for predicting treatment effectiveness of vedolizumab (VDZ) in Crohn’s disease. AIM: To assess the utility of this CDST for predicting exposure‐efficacy and disease outcomes. METHODS: Using data from three independent datasets (G...

Descripción completa

Detalles Bibliográficos
Autores principales: Dulai, Parambir S., Amiot, Aurelien, Peyrin‐Biroulet, Laurent, Jairath, Vipul, Serrero, Melanie, Filippi, Jerome, Singh, Siddharth, Pariente, Benjamin, Loftus, Edward V., Roblin, Xavier, Kane, Sunanda, Buisson, Anthony, Siegel, Corey A., Bouhnik, Yoram, Sandborn, William J., Lasch, Karen, Rosario, Maria, Feagan, Brian G., Bojic, Daniela, Trang‐Poisson, Caroline, Shen, Bo, Altwegg, Romain, Sands, Bruce E., Colombel, Jean‐Frederic, Carbonnel, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Optimising Vedolizumab in Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028036/
https://www.ncbi.nlm.nih.gov/pubmed/31867766
http://dx.doi.org/10.1111/apt.15609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028036/
https://www.ncbi.nlm.nih.gov/pubmed/31867766
http://dx.doi.org/10.1111/apt.15609

Ejemplares similares